NCT02773030: Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM
Updated: Feb 10
CC-220-MM-001
NDMM
Newly Diagnosed Multiple Myeloma
RRMM
Relapsed Refractory Multiple Myeloma
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02773030: Phase 1/2: A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Iberdomide
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.
Sponsor
Multiple locations
International Study
ClinicalTrials.gov Identifier: NCT02773030
Official Title: A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
First Posted : May 16, 2016
Click here to see details on ClinicalTrials.gov
First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
ASCO Abstract
First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood Volume 136, Issue Supplement 1
November 5 2020
162 Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Novel Targets and Amyloid
Hematology Disease Topics & Pathways:
Clinical Trials, Biological, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies
Saturday, December 11, 2021: 1:15 PM
11/04/2021: PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in Atlanta, Georgia, and virtually, from December 11 to 14, 2021. Data from more than 80 company-sponsored studies will be featured, including 23 oral presentations, highlighting key research and development programs in lymphomas, leukemias, multiple myeloma and myeloid diseases, and showcasing our commitment to delivering transformative medicines across major hematologic diseases.
First disclosure of safety and efficacy results from dose expansion of the MM-001 study evaluating CELMoD® iberdomide in combination with dexamethasone in patients with R/R multiple myeloma
Click here for details.
Drug: CC-220
CRL4 cereblon E3 ubiquitin ligase modulator CC-220
Drug: Dexamethasone
Drug: Daratumumab - 16mg/kg
Drug: Bortezomib (BTZ)
Drug: Carfilzomib
Drug: Daratumumab- 1800mg
- Arizona: Mayo Clinic Arizona
- Arkansas: University of Arkansas Little Rock
- Georgia: Emory University Atlanta
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- Massachusetts: Massachusetts General Hospital Boston
- Michigan: Barbara Ann Karmanos Cancer Institute Detroit
- New Jersey: Hackensack University Medical Center
- New York: New York Presbyterian / Weill Cornell Medical College New York
- New York: NYU Langone Medical Center New York
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- New York: University of Rochester New York
- Texas: UT Southwestern Medical Center Dallas
Locations
United States, Arizona
United States, Arkansas
United States, Georgia
United States, Illinois
United States, Kansas
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, New Jersey
United States, New York
United States, North Carolina
United States, Ohio
United States, Pennsylvania
United States, South Carolina
United States, Texas
United States, Utah
Canada, Alberta
Canada, British Columbia
Canada, Nova Scotia
Canada, Quebec
Europe
United Kingdom
France
Germany
Italy
Netherlands
Spain
Asia
Japan
Israel